[Form 4] Streamline Health Solutions, Inc. Insider Trading Activity
Streamline Health Solutions director Justin J. Ferayorni reported dispositions tied to a merger that became effective on 08/12/2025. Under the Merger Agreement, each outstanding share of common stock was canceled and converted into the right to receive $5.34 in cash, and the company became a wholly owned subsidiary of Mist Holding Co.
The Form 4 lists dispositions of common stock held directly and indirectly (reported as 78,416 shares direct and 92,294 shares indirect via Tamarack Advisers) and reports cancellation of 29,914 warrants with a $5.85 exercise price. The filing notes that warrants with exercise prices equal to or above the $5.34 Merger Consideration were canceled for no consideration and shows reported post-transaction beneficial ownership of the listed securities as 0.
Justin J. Ferayorni, direttore di Streamline Health Solutions, ha segnalato cessioni legate a una fusione divenuta effettiva il 08/12/2025. In base all'Accordo di Fusione, ogni azione ordinaria in circolazione è stata annullata e convertita nel diritto di ricevere $5.34 in contanti, e la società è diventata una controllata interamente posseduta da Mist Holding Co.
Il Form 4 indica cessioni di azioni ordinarie detenute direttamente e indirettamente (riportate come 78,416 azioni dirette e 92,294 azioni indirette tramite Tamarack Advisers) e segnala l'annullamento di 29,914 warrant con prezzo di esercizio di $5.85. Il deposito precisa che i warrant con prezzi di esercizio pari o superiori alla considerazione di fusione di $5.34 sono stati cancellati senza alcuna contropartita e mostra la partecipazione beneficiaria post-operazione delle relative securities pari a 0.
Justin J. Ferayorni, director de Streamline Health Solutions, declaró enajenaciones vinculadas a una fusión que entró en vigor el 08/12/2025. Según el Acuerdo de Fusión, cada acción ordinaria en circulación fue cancelada y convertida en el derecho a recibir $5.34 en efectivo, y la compañía pasó a ser una filial de propiedad total de Mist Holding Co.
El Form 4 enumera enajenaciones de acciones ordinarias poseídas directa e indirectamente (informadas como 78,416 acciones directas y 92,294 acciones indirectas a través de Tamarack Advisers) y reporta la cancelación de 29,914 warrants con precio de ejercicio de $5.85. La presentación señala que los warrants con precios de ejercicio iguales o superiores a la consideración de fusión de $5.34 fueron cancelados sin compensación y muestra una propiedad beneficiaria posterior a la transacción de los valores listados de 0.
Streamline Health Solutions의 이사 Justin J. Ferayorni는 2025년 08월 12일자로 효력이 발생한 합병과 관련된 처분을 보고했습니다. 합병계약에 따라 발행 중인 각 보통주는 소각되어 현금 $5.34를 수령할 권리로 전환되었고, 회사는 Mist Holding Co.의 완전 자회사가 되었습니다.
Form 4에는 직접 및 간접 보유된 보통주에 대한 처분이 기재되어 있으며(직접 78,416주, Tamarack Advisers를 통한 간접 92,294주로 보고) 행사가 $5.85인 워런트 29,914건의 소각을 보고하고 있습니다. 제출 문서에는 행사가가 $5.34 합병 대가와 같거나 높은 워런트는 대가 없이 취소되었으며, 거래 후 해당 증권에 대한 보고된 실질적 소유는 0으로 표시되어 있다고 명시되어 있습니다.
Justin J. Ferayorni, directeur de Streamline Health Solutions, a déclaré des cessions liées à une fusion entrée en vigueur le 08/12/2025. En vertu de l'accord de fusion, chaque action ordinaire en circulation a été annulée et convertie en le droit de recevoir $5.34 en espèces, et la société est devenue une filiale détenue à 100 % par Mist Holding Co.
Le Form 4 énumère des cessions d'actions ordinaires détenues directement et indirectement (déclarées comme 78,416 actions en direct et 92,294 actions en indirect via Tamarack Advisers) et signale l'annulation de 29,914 warrants avec un prix d'exercice de $5.85. Le dépôt précise que les warrants dont le prix d'exercice est égal ou supérieur à la contrepartie de fusion de $5.34 ont été annulés sans contrepartie et indique une détention bénéficiaire après transaction des titres listés de 0.
Justin J. Ferayorni, Direktor von Streamline Health Solutions, meldete Veräußerungen im Zusammenhang mit einer Fusion, die am 08/12/2025 wirksam wurde. Gemäß dem Fusionsvertrag wurde jede ausstehende Stammaktie annulliert und in das Recht umgewandelt, $5.34 in bar zu erhalten, und das Unternehmen wurde eine hundertprozentige Tochtergesellschaft von Mist Holding Co.
Das Form 4 führt Veräußerungen von direkt und indirekt gehaltenen Stammaktien auf (gemeldet als 78,416 Aktien direkt und 92,294 Aktien indirekt über Tamarack Advisers) und verzeichnet die Annullierung von 29,914 Warrants mit einem Ausübungspreis von $5.85. Die Einreichung weist darauf hin, dass Warrants mit Ausübungspreisen gleich oder über dem Fusionsgegenwert von $5.34 ohne Gegenleistung annulliert wurden, und zeigt das nach der Transaktion gemeldete wirtschaftliche Eigentum an den aufgeführten Wertpapieren mit 0.
- Merger provided immediate cash consideration of $5.34 per outstanding common share, delivering liquidity to shareholders.
- The Merger Agreement explicitly specifies treatment of warrants, providing clarity on cash conversion or cancellation outcomes for holders.
- Outstanding warrants with an exercise price equal to or above $5.34 (including 29,914 at $5.85) were canceled for no consideration.
- The company became a wholly owned subsidiary and listed common shares were canceled, eliminating ongoing public equity positions for holders
Insights
TL;DR: Merger completed; public shares converted to $5.34 cash and outstanding warrants were either cashed out or canceled, ending public equity positions.
The Form 4 documents a change-of-control transaction effective 08/12/2025 in which Streamline Health became a wholly owned subsidiary of Mist Holding Co. Each outstanding common share was converted into the right to receive $5.34 in cash. Reported dispositions include 78,416 direct shares and 92,294 indirect shares. The filing also records 29,914 warrants at a $5.85 exercise price; per the Merger Agreement, warrants with exercise prices equal to or above the Merger Consideration were canceled for no consideration. This is a material corporate liquidity event that resolves public holders’ exposure by cash settlement.
TL;DR: Insider filings show director-level holdings held via adviser and family trust were disposed in the merger, with post-transaction ownership reported as zero.
The Form 4 attributes indirect holdings to Tamarack Advisers, LP and direct holdings to The Ferayorni Family Trust, with Mr. Ferayorni identified as managing member/co-trustee. The report indicates the listed common stock positions were canceled and converted into cash, and related warrants were canceled per contract terms. The disclosure is specific about ownership pathways and post-transaction balances, showing no remaining reported beneficial ownership of the listed securities.
Justin J. Ferayorni, direttore di Streamline Health Solutions, ha segnalato cessioni legate a una fusione divenuta effettiva il 08/12/2025. In base all'Accordo di Fusione, ogni azione ordinaria in circolazione è stata annullata e convertita nel diritto di ricevere $5.34 in contanti, e la società è diventata una controllata interamente posseduta da Mist Holding Co.
Il Form 4 indica cessioni di azioni ordinarie detenute direttamente e indirettamente (riportate come 78,416 azioni dirette e 92,294 azioni indirette tramite Tamarack Advisers) e segnala l'annullamento di 29,914 warrant con prezzo di esercizio di $5.85. Il deposito precisa che i warrant con prezzi di esercizio pari o superiori alla considerazione di fusione di $5.34 sono stati cancellati senza alcuna contropartita e mostra la partecipazione beneficiaria post-operazione delle relative securities pari a 0.
Justin J. Ferayorni, director de Streamline Health Solutions, declaró enajenaciones vinculadas a una fusión que entró en vigor el 08/12/2025. Según el Acuerdo de Fusión, cada acción ordinaria en circulación fue cancelada y convertida en el derecho a recibir $5.34 en efectivo, y la compañía pasó a ser una filial de propiedad total de Mist Holding Co.
El Form 4 enumera enajenaciones de acciones ordinarias poseídas directa e indirectamente (informadas como 78,416 acciones directas y 92,294 acciones indirectas a través de Tamarack Advisers) y reporta la cancelación de 29,914 warrants con precio de ejercicio de $5.85. La presentación señala que los warrants con precios de ejercicio iguales o superiores a la consideración de fusión de $5.34 fueron cancelados sin compensación y muestra una propiedad beneficiaria posterior a la transacción de los valores listados de 0.
Streamline Health Solutions의 이사 Justin J. Ferayorni는 2025년 08월 12일자로 효력이 발생한 합병과 관련된 처분을 보고했습니다. 합병계약에 따라 발행 중인 각 보통주는 소각되어 현금 $5.34를 수령할 권리로 전환되었고, 회사는 Mist Holding Co.의 완전 자회사가 되었습니다.
Form 4에는 직접 및 간접 보유된 보통주에 대한 처분이 기재되어 있으며(직접 78,416주, Tamarack Advisers를 통한 간접 92,294주로 보고) 행사가 $5.85인 워런트 29,914건의 소각을 보고하고 있습니다. 제출 문서에는 행사가가 $5.34 합병 대가와 같거나 높은 워런트는 대가 없이 취소되었으며, 거래 후 해당 증권에 대한 보고된 실질적 소유는 0으로 표시되어 있다고 명시되어 있습니다.
Justin J. Ferayorni, directeur de Streamline Health Solutions, a déclaré des cessions liées à une fusion entrée en vigueur le 08/12/2025. En vertu de l'accord de fusion, chaque action ordinaire en circulation a été annulée et convertie en le droit de recevoir $5.34 en espèces, et la société est devenue une filiale détenue à 100 % par Mist Holding Co.
Le Form 4 énumère des cessions d'actions ordinaires détenues directement et indirectement (déclarées comme 78,416 actions en direct et 92,294 actions en indirect via Tamarack Advisers) et signale l'annulation de 29,914 warrants avec un prix d'exercice de $5.85. Le dépôt précise que les warrants dont le prix d'exercice est égal ou supérieur à la contrepartie de fusion de $5.34 ont été annulés sans contrepartie et indique une détention bénéficiaire après transaction des titres listés de 0.
Justin J. Ferayorni, Direktor von Streamline Health Solutions, meldete Veräußerungen im Zusammenhang mit einer Fusion, die am 08/12/2025 wirksam wurde. Gemäß dem Fusionsvertrag wurde jede ausstehende Stammaktie annulliert und in das Recht umgewandelt, $5.34 in bar zu erhalten, und das Unternehmen wurde eine hundertprozentige Tochtergesellschaft von Mist Holding Co.
Das Form 4 führt Veräußerungen von direkt und indirekt gehaltenen Stammaktien auf (gemeldet als 78,416 Aktien direkt und 92,294 Aktien indirekt über Tamarack Advisers) und verzeichnet die Annullierung von 29,914 Warrants mit einem Ausübungspreis von $5.85. Die Einreichung weist darauf hin, dass Warrants mit Ausübungspreisen gleich oder über dem Fusionsgegenwert von $5.34 ohne Gegenleistung annulliert wurden, und zeigt das nach der Transaktion gemeldete wirtschaftliche Eigentum an den aufgeführten Wertpapieren mit 0.